Hamilton Thorne (CN: HTL-V) FDA Clearance for Clinical Applications
Multi-Pulse software has received FDA clearance for performing embryo biopsy in clinical settings
HTL-V’s Multi-Pulse feature provides rapid, repeated firing of the laser to facilitate removal of cells from an embryo during the trophectoderm biopsy process. Trophectoderm biopsy removes cells from the embryos of patients undergoing pre-implantation genetic diagnosis (PGD) to screen for genetic disease or aneuploidy.
The Bottom Line: The Multi-Pulse capability provides the user with the ability to automatically fire the laser multiple times at relatively low power, will contribute significantly to the efficiency and safety of trophectoderm biopsy. Prior to release of the Multi-pulse software, individual laser shots were required to weaken or break the junctions between the trophectoderm cells so that they can be aspirated into the biopsy micropipette. The significant advantage of Multi-Pulse is that one press of the remote footswitch initiates multiple laser pulses in rapid succession for fast and easy cell separation, thereby limiting the amount of time the embryo spends outside the incubator. HTl-V is trading at $0.15 in flat range.
